Companies
/Healthcare
Supernus Pharmaceuticals Inc
$40.70
▼ $1.37 (−3.26%) today
Markets closed · 5:24am ET
SUPN at a Glance
Valuation
- Market cap
- $2.4B
Profitability
- Revenue (TTM)
- $830.4M
- Profit margin
- -13.2%
- EPS (TTM)
- $-1.96
Price
- 52-week range
- $38 – $60
- Street target
- $60.50
Earnings
- Next report
- Oct 29, 2026
Headquartered in Rockville, MD Fiscal year ends December NASDAQ: SUPN supernus.com
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD) with Qelbree and SPN-443 in development, dyskinesia in Parkinson's disease patients receiving levodopa-based therapy with GOCOVRI, hypomobility in Parkinson's disease with ONAPGO, postpartum depression with ZURZUVAE (marketed through a collaboration with Biogen), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company markets legacy products Trokendi XR and Oxtellar XR for epilepsy and is advancing a pipeline of novel CNS candidates including SPN-817 for treatment-resistant epilepsy, SPN-820 for major depressive disorder, and SPN-443 for ADHD. Supernus has announced a definitive agreement for an all-stock merger of equals with Indivior Pharmaceuticals, a company focused on long-acting injectable treatments for opioid use disorder, which would create a diversified CNS biopharmaceutical company with significant scale. Updated
Frequently Asked Questions
What does Supernus Pharmaceuticals do?
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
What is the SUPN stock price target?
The Wall Street consensus 12-month price target for SUPN is $60.50.